Literature DB >> 627526

Biological and chemotherapeutic studies on three semisynthetic cephamycins.

J V Uri, P Actor, J R Guarini, L Phillips, D Pitkin, R M Demarinis, J A Weisbach.   

Abstract

Three semisynthetic cephamycin antibiotics (7alpha-methoxy-cephalosporins), SK&F 73678, SK&F 83088 (CS-1170) and cefoxitin, have been found to possess favorable biological and chemotherapeutic properties. All three cephamycins are active in vitro against strains of Staphylococcus aureus and a variety of gram-negative bacilli. Beta-lactamase producing organisms including indole-producing Proteus spp., Enterobacter spp. and Serratia strains as well as certain anaerobic bacteria were found to be susceptible to these antibiotics. SK&F 73768 showed somewhat better MIC values than cefoxitin against multiple strains of bacteria. Strains of Pseudomonas aeruginosa and group D streptococci are essentially insensitive to these compounds. Their binding to serum proteins is relatively low. In mice, cefoxitin showed the most favorable pharmacokinetics with respect to peak serum level, serum half-life and urinary recovery. These cephamycins protected mice experimentally infected with a variety of bacterial strains. All three compounds are rapidly bacteriolytic to the logarithmically growing Escherichia coli and belatedly so to Staphylococcus strains with complete sterilizing effect. SK&F 73678 and SK&F 83088 showed activity and potency comparable to or better than cefoxitin and thus can be considered candidates for clinical study.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 627526     DOI: 10.7164/antibiotics.31.82

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  3 in total

1.  Pharmacokinetic parameters from data relating to the plasma and biliary excretion kinetics of cefmetazole in rats.

Authors:  M J García-Agundez; C Fernández-Lastra; R Jiménez; J González; E L Mariño
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

Review 2.  Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

3.  Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation.

Authors:  T Yoshida; S Matsuura; M Mayama; Y Kameda; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.